SCHEDULE 13G/A: BlackRock Discloses 3.7% Passive Stake in Applied Therapeutics

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 3.7% beneficial ownership stake in Applied Therapeutics Inc., held as a passive investment.

Summary

• BlackRock, Inc. reported beneficial ownership of 5,219,475 common shares of APPLIED THERAPEUTICS INC., representing 3.7% of the class.
• The filing, an Amendment No. 2 to Schedule 13G, indicates that BlackRock holds these securities in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• BlackRock, Inc. maintains sole voting power over 5,195,137 shares and sole dispositive power over 5,219,475 shares.
• The event date requiring this filing was June 30, 2025, with the statement filed on July 16, 2025.
• Various BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are identified as entities that acquired the security, though no single subsidiary beneficially owns 5% or greater of the outstanding shares.

Sentiment

Score: 5

Explanation: A routine beneficial ownership filing, indicating a passive investment stake by a large institutional investor. It does not convey positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a routine disclosure by a large institutional investor, BlackRock, Inc., regarding its passive ownership stake in a publicly traded company. It reflects standard portfolio management activities rather than a strategic industry move or a significant shift in market dynamics for Applied Therapeutics Inc.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake, confirming no intent to influence control.

Key Dates

Keywords

BlackRock, Applied Therapeutics, Schedule 13G, Beneficial Ownership, Passive Investment, Common Stock, Institutional Investor, SEC Filing